CRISPR Therapeutics (CRSP)

• Market cap: $3.38B
• 1 day: 1.48%
• 5 days: 5.05%
• 1 month: -8.24%
• 3 months: -9.93%
• 6 months: -18.44%
• Year to date: -5.60%
• 1 year: -29.72%
• 5 years: -27.59%
• 10 years: 177.57%
• Sector: Healthcare
• Industry: Biotechnology

About: Crispr Therapeutics AG is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.

Employees: 393

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

5.77% more ownership

Funds ownership: 69.81% [Q3] → 75.59% (+5.77%) [Q4]

6% less first-time investments, than exits

New positions opened: 65 | Existing positions closed: 69

6% less repeat investments, than reductions

Existing positions increased: 112 | Existing positions reduced: 119

3% less funds holding

Funds holding: 409 [Q3] → 396 (-13) [Q4]

9% less capital invested

Capital invested by funds: $2.79B [Q3] → $2.54B (-$251M) [Q4]

11% less call options, than puts

Call options by funds: $81.6M | Put options by funds: $91.6M

20% less funds holding in top 10

Funds holding in top 10: 5 [Q3] → 4 (-1) [Q4]

Research analyst outlook

12 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $32 18% downside
• Avg. target: $72 84% upside
• High target: $120 207% upside

12 analyst ratings

• positive: 7 58%
• neutral: 4 33%
• negative: 1 8%

Needham Gil Blum 16% 1-year accuracy 25 / 157 met price target	115% upside $84	Buy Reiterated	9 Apr 2025
Citigroup Yigal Nochomovitz 15% 1-year accuracy 6 / 41 met price target	110% upside $82	Buy Maintained	18 Feb 2025
Morgan Stanley Terence Flynn 29% 1-year accuracy 6 / 21 met price target	18% downside $32	Underweight Maintained	14 Feb 2025
Evercore ISI Group Liisa Bayko 44% 1-year accuracy 4 / 9 met price target	153% upside $99	Outperform Upgraded	14 Feb 2025
Goldman Sachs Salveen Richter 16% 1-year accuracy 3 / 19 met price target	46% upside $57	Neutral Maintained	13 Feb 2025